Tibet Aim Pharm Inc (002826) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tibet Aim Pharm Inc (002826) has a cash flow conversion efficiency ratio of 0.109x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥87.55 Million ≈ $12.81 Million USD) by net assets (CN¥802.15 Million ≈ $117.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tibet Aim Pharm Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Tibet Aim Pharm Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Tibet Aim Pharm Inc carry for a breakdown of total debt and financial obligations.
Tibet Aim Pharm Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tibet Aim Pharm Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Fangzheng Automobile Mould Co.Ltd.
SHE:300998
|
0.023x |
|
C.E. Info Systems Limited
NSE:MAPMYINDIA
|
0.054x |
|
Hangzhou Seck Intelligent Tech Co
SHE:300897
|
0.038x |
|
Huaren Pharmaceutical Co Ltd
SHE:300110
|
0.061x |
|
Vietnam Construction and Import Export JSC
VN:VCG
|
0.078x |
|
India Tourism Development Corporation Limited
NSE:ITDC
|
0.016x |
|
SAPPI LTD ADR/1 RC 1
F:SPIA
|
N/A |
|
Dare Technology Co Ltd
SHE:000910
|
0.003x |
Annual Cash Flow Conversion Efficiency for Tibet Aim Pharm Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Tibet Aim Pharm Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Tibet Aim Pharm Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥745.58 Million ≈ $109.10 Million |
CN¥111.57 Million ≈ $16.33 Million |
0.150x | -32.74% |
| 2023-12-31 | CN¥750.06 Million ≈ $109.76 Million |
CN¥166.88 Million ≈ $24.42 Million |
0.222x | +143.77% |
| 2022-12-31 | CN¥750.00 Million ≈ $109.75 Million |
CN¥68.45 Million ≈ $10.02 Million |
0.091x | -39.99% |
| 2021-12-31 | CN¥720.11 Million ≈ $105.37 Million |
CN¥109.52 Million ≈ $16.03 Million |
0.152x | +2.73% |
| 2020-12-31 | CN¥687.15 Million ≈ $100.55 Million |
CN¥101.74 Million ≈ $14.89 Million |
0.148x | +63.10% |
| 2019-12-31 | CN¥652.17 Million ≈ $95.43 Million |
CN¥59.20 Million ≈ $8.66 Million |
0.091x | +321.64% |
| 2018-12-31 | CN¥618.40 Million ≈ $90.49 Million |
CN¥13.31 Million ≈ $1.95 Million |
0.022x | -83.16% |
| 2017-12-31 | CN¥604.53 Million ≈ $88.46 Million |
CN¥77.29 Million ≈ $11.31 Million |
0.128x | +24.19% |
| 2016-12-31 | CN¥555.44 Million ≈ $81.28 Million |
CN¥57.18 Million ≈ $8.37 Million |
0.103x | +186.07% |
| 2015-12-31 | CN¥248.25 Million ≈ $36.33 Million |
CN¥-29.69 Million ≈ $-4.34 Million |
-0.120x | -1080.84% |
| 2014-12-31 | CN¥179.12 Million ≈ $26.21 Million |
CN¥2.18 Million ≈ $319.61K |
0.012x | -98.33% |
| 2013-12-31 | CN¥71.66 Million ≈ $10.49 Million |
CN¥52.24 Million ≈ $7.64 Million |
0.729x | -- |
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more